

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Comparison of the effect of Evening primrose oil with vaginal misoprostol in softening of the cervix in patients candidate for myomectomy hysteroscopy in Yas Hospital 2020-2022: a Randomized Clinical Trial

#### Protocol summary

##### Study aim

1. Comparison of Hegar dilator size used in Evening primrose oil group with misoprostol group 2. Determining the side effects caused by Evening primrose oil and misoprostol

##### Design

This phase 3 clinical trial with a control group, with parallel groups, double-blind, randomized using the Random allocation rule is performed on 118 patients.

##### Settings and conduct

In this randomized clinical trial study, which is performed on 118 patients who are candidates for myomectomy hysteroscopy in Yas Hospital from 2020 to 2022. The sampling method is a convenience method. This study is performed as a double-blind study, the surgeon (the person performing the hysteroscopy) and the patient do not know the type of treatment. The drug is used by the resident physician for the patient based on the patient group the night before the hysteroscopy.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria include all non-menopausal nulliparous women or gravid one women with a history of one cesarean section in the age group of 25 to 75 years. Criteria for not entering: Allergy or contraindication to Evening primrose oil or misoprostol

##### Intervention groups

In 59 patients 6 hours before hysteroscopy, for cervical ripening, two 500 mg Evening primrose oil capsules will be placed in the posterior part of the vagina, also, 200 micrograms of vaginal misoprostol will be used in the same way.

##### Main outcome variables

- Hegar dilator size used during hysteroscopy - Time to dilatation after taking the drug - Side effects following medication consumption

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20201028049169N1**

Registration date: **2020-11-02, 1399/08/12**

Registration timing: **prospective**

Last update: **2020-11-02, 1399/08/12**

Update count: **0**

##### Registration date

2020-11-02, 1399/08/12

##### Registrant information

##### Name

Elham Feizabad

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 8608 9092

##### Email address

elhamfeizabad@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2020-11-21, 1399/09/01

##### Expected recruitment end date

2022-11-21, 1401/08/30

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

## Scientific title

Comparison of the effect of Evening primrose oil with vaginal misoprostol in softening of the cervix in patients candidate for myomectomy hysteroscopy in Yas Hospital 2020-2022: a Randomized Clinical Trial

## Public title

Comparison of the effect of Evening primrose oil with vaginal misoprostol in softening of the cervix before myomectomy hysteroscopy in Yas Hospital

## Purpose

Treatment

## Inclusion/Exclusion criteria

### Inclusion criteria:

All non-menopausal nulliparous women or Gravid One women with a history of one cesarean section The age group of 25 to 75 years

### Exclusion criteria:

people with a history of schizophrenia or epilepsy taking phenothiazines, structural cervical abnormalities such as a history of cervical insufficiency, Müllerian anomaly, and history of conization The unwillingness of people to participate in the study Allergy to Evening primrose oil or misoprostol contraindications for Evening primrose oil or misoprostol using such as coagulation disorders or concomitant consumption of anticoagulants drug

## Age

From **25 years** old to **75 years** old

## Gender

Female

## Phase

3

## Groups that have been masked

- Outcome assessor
- Data analyser

## Sample size

Target sample size: **118**

## Randomization (investigator's opinion)

Randomized

## Randomization description

Random allocation rule: First, 59 letters A and 59 letters B are written on special papers that are not marked inside. Then all of them are placed in a bag and for each patient, after obtaining informed consent, a paper is removed randomly and without replacement, and based on the letter written on it, the desired intervention is performed for the patient. In addition, interventions A or B are determined by a lot.

## Blinding (investigator's opinion)

Double blinded

## Blinding description

This study is performed as double-blind, the surgeon (the person performing the hysteroscopy), and the analyzer do not know the type of treatment. The drug is used by the resident physician for the patient based on the patient group the night before the hysteroscopy.

## Placebo

Not used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Tehran University of Medical Sciences

##### Street address

ehran University of Medical Sciences,School of Medicine, Tehran Province, Tehran, Pour Sina St" to "Tehran University of Medical Sciences,School of Medicine, Tehran Province, Tehran, Pour Sina St

##### City

Tehran

##### Province

Tehran

##### Postal code

1598718311

#### Approval date

2020-10-12, 1399/07/21

#### Ethics committee reference number

IR.TUMS.MEDICINE.REC.1399.611

## Health conditions studied

### 1

#### Description of health condition studied

Uterine Leiomyoma

#### ICD-10 code

D25

#### ICD-10 code description

Leiomyoma of uterus

## Primary outcomes

### 1

#### Description

The cervix dilatation measurement

#### Timepoint

Once, Before hysteroscopy

#### Method of measurement

The Hegar dilator size using for hysteroscopy

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: 6 hours before hysteroscopy for cervix ripening, 200 micrograms of vaginal misoprostol from Samisaz pharmaceutical company is placed in the

posterior part of the vagina.

**Category**

Treatment - Drugs

**2****Description**

Control group: 6 hours before hysteroscopy for cervix ripening two 500 mg capsules of Evening primrose oil from Daana pharmaceutical company is placed in the posterior part of the vagina.

**Category**

Treatment - Drugs

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Yas hospital

**Full name of responsible person**

Mehrnaz Valadan

**Street address**

Yas hospital, Next to the sarv street , North Nejatollahi street , karim khan ave

**City**

Tehran

**Province**

Tehran

**Postal code**

1597856511

**Phone**

+98 21 8608 9089

**Fax****Email**

mehrnaz\_valadan@yahoo.com

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Mehrnaz Valadan

**Street address**

Yas hospital, Next to the sarv street , North Nejatollahi street , karim khan ave

**City**

Tehran

**Province**

Tehran

**Postal code**

1597856511

**Phone**

+98 21 8608 9089

**Email**

mehrnaz\_valadan@yahoo.com

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Tehran University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin****Type of organization providing the funding**

Academic

**Person responsible for general inquiries****Contact****Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Sahar Garfami

**Position**

resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

Yas hospital, Next to the sarv street , North Nejatollahi street , karim khan ave

**City**

Tehran

**Province**

Tehran

**Postal code**

1597856511

**Phone**

+98 21 8608 9089

**Email**

sahar.garfami87@yahoo.com

**Person responsible for scientific inquiries****Contact****Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Mehrnaz Valadan

**Position**

Associate professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Gynecology and Obstetrics

**Street address**

Yas hospital, Next to the sarv street , North Nejatollahi street , karim khan ave

**City**

Tehran  
**Province**  
Tehran  
**Postal code**  
1597856511  
**Phone**  
+98 21 8608 9089  
**Email**  
mehrnaz\_valadan@yahoo.com

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Tehran University of Medical Sciences  
**Full name of responsible person**  
Elham Feizabad  
**Position**  
Researcher  
**Latest degree**  
Specialist  
**Other areas of specialty/work**  
Public Health/Community Medicine  
**Street address**  
Yas hospital, Next to the sarv street , North  
Nejatollahi street , karim khan ave  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1598718311  
**Phone**  
+98 21 8608 9089  
**Email**  
elhamfeizabad@gmail.com

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

### Study Protocol

Yes - There is a plan to make this available

### Statistical Analysis Plan

Yes - There is a plan to make this available

### Informed Consent Form

Yes - There is a plan to make this available

### Clinical Study Report

Yes - There is a plan to make this available

### Analytic Code

Yes - There is a plan to make this available

### Data Dictionary

Not applicable

### Title and more details about the data/document

All data is potentially shareable after unidentified participants

### When the data will become available and for how long

After manuscript published

### To whom data/document is available

No limitations

### Under which criteria data/document could be used

The data is only available to the project manager, Dr. Valdan, and any analysis must be done with her opinion.

### From where data/document is obtainable

Dr. Mehrnaz Valdan

### What processes are involved for a request to access data/document

Any request must be made in writing and accompanied by a proposal with an ethics code under the supervision of Dr. Valdan.

### Comments